Prostate Cancer Clinical Trials

Showing 801-820 of 2,150 trials

Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy

NCT02099864

This phase II trial studies genetic and molecular mechanisms in assessing response in patients with prostate cancer receiving enzalutamide therapy. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as enzalutamide, may lessen the amount of androgens made by the body. Studying samples of tissue and blood in the laboratory from patients with prostate cancer may help doctors better understand castration-resistant prostate cancer. It may also help doctors make improvements in prostate cancer treatment.

Castration-Resistant Prostate CarcinomaMetastatic Malignant Neoplasm in the BoneMetastatic Malignant Neoplasm in the Soft Tissues+4 more

OHSU Knight Cancer Institute36 participantsStarted Feb 2014

San Francisco, California, United States • Portland, Oregon, United States

TERMINATEDNA

Combination of Serum Measurements of Molecular Biomarkers and Serum Protein Profiling Can be Used to Predict Which Patients Undergoing Prostatic Biopsy Will be Diagnosed With Cancer

NCT00773773

This is a prospective, serum proteomics study of men who are to undergo prostate biopsy. The purpose is to determine if proteomic profiles can be used to distinguish between men with prostate cancer on biopsy from men with no cancer on biopsy.

Prostate CancerElevated Prostate Specific Antigen (PSA)

Memorial Sloan Kettering Cancer Center58 participantsStarted Oct 2008

Brooklyn, New York, United States • Brooklyn, New York, United States • New York, New York, United States +1 more locations

Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy

Combination of Serum Measurements of Molecular Biomarkers and Serum Protein Profiling Can be Used to Predict Which Patients Undergoing Prostatic Biopsy Will be Diagnosed With Cancer

Related Searches

Intramuscular Mechanisms of Androgen Deprivation-related Sarcopenia

Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer

Radiation Therapy in Treating Patients With Relapsed Prostate Cancer After Surgery

Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)

Stockholm3 Use Prior to MRI for Prostate Cancer Detection in a Clinical Care Pathway: a Multi-centered Validation

Radical Hypofractionated Radiotherapy for Localized Prostate Cancer

Can MRI of the Prostate Combined With a Radiomics Evaluation Determine the Invasive Capacity of a Tumour

ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid Tumors

PSMA Specific [68Ga]-P137 Peptide Probe for PET Imaging in Prostate Cancer

HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors

Assessments of Genetic Counseling Augmented With an Educational Video or Pamphlet Versus Traditional Counseling

The Impact of Medication Timing Adjustment on the Effect of Novel Hormonal Therapy

Observation of Clinical Consistency of Organoid-chips Drug Sensitivity in Chemotherapy for PCa With Visceral Metastasis

Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients

pCHIP: Prostate Cancer Health Impact Program

Transpelvic Magnetic Stimulation to Improve Urogenital Function